The Universal lateral-flow assay (LFA) kit from Sygnis AG, Cambridge, UK, is the latest addition to the company’s expanding range of lateral-flow assay products and services commercialized under the Innova Biosciences brand name.
Sygnis’s new product provides a tool for the quick development of customized sandwich lateral-flow assays. The company has filed a patent application to protect its newly developed product and technology.
The kit aims to enable researchers to streamline research and development for their diagnostic tests, speeding the development of point-of-care diagnostic tools for entry into this growing market.
The kit utilizes the company’s patented antibody labeling technologies, Lightning-Link and InnovaCoat Gold, and enables customers to create lateral-flow assay reagents with only a few minutes of hands-on time, and without the need to spray capture antibodies on the test strip.
Within the Universal LFA kit, the Lightning-Link technology enables quick and easy labeling of up to three analyte capture antibodies of the customers’ choice. InnovaCoat Gold technology is used for covalent conjugation of up to three detection antibodies to ultra-high quality gold nanoparticles.
“The launch of the Universal LFA kit is a novel addition to Sygnis’s rapidly expanding range of lateral-flow assay products and services,” says Nick Gee, chief technology officer at Sygnis. “This new kit massively simplifies and accelerates assay development—in addition to reducing costs—ultimately benefiting anyone that works with lateral-flow assays.”
For more information, visit Innova Biosciences.